OR WAIT null SECS
April 14, 2021
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
March 24, 2021
NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
March 19, 2021
Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.
March 11, 2021
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
March 08, 2021
Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
January 18, 2021
How engaging with digital influencers holds the key for medical affairs.
December 18, 2020
If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.
November 11, 2020
Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.
October 14, 2020
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Tips for rounding out the rough edges in crossover.
October 13, 2020
Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.
September 30, 2020
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
September 29, 2020
Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
September 20, 2020
Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.
September 14, 2020
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
Uncovering fish oil derivative’s benefit for heart health.
New hope accompanies overdue recognition in sickle cell disease fight.
The world’s most expensive drug put in context.
